Viking Therapeutics Inc
1VT
Company Profile
Business description
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Contact
9920 Pacific Heights Boulevard
Suite 350
San DiegoCA92121
USAT: +1 858 704-4660
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
51
Stocks News & Analysis
stocks
PayPal earnings: Growth slows, new CEO appointed
We expect to lower our fair value estimate of PayPal stock.
stocks
Morningstar initiates on ASX income play
This REIT may be an option for investors seeking income.
stocks
What Goodman’s upcoming earnings could reveal about data centre & AI growth
Answering key questions about Goodman & its data centre pipeline ahead of earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,204.60 | 56.50 | 0.62% |
| CAC 40 | 8,263.16 | 83.66 | 1.02% |
| DAX 40 | 24,638.18 | 142.61 | -0.58% |
| Dow JONES (US) | 49,499.95 | 258.96 | 0.53% |
| FTSE 100 | 10,475.66 | 161.07 | 1.56% |
| HKSE | 26,847.32 | 12.55 | 0.05% |
| NASDAQ | 23,121.29 | 133.90 | -0.58% |
| Nikkei 225 | 54,293.36 | 427.30 | -0.78% |
| NZX 50 Index | 13,467.29 | 54.85 | 0.41% |
| S&P 500 | 6,911.93 | 5.88 | -0.09% |
| S&P/ASX 200 | 8,927.80 | 75.50 | 0.85% |
| SSE Composite Index | 4,102.20 | 34.46 | 0.85% |